Notifiche
Cancella tutti

Gadoteridol Gd-HP-DO3A

1 Post
1 Utenti
0 Reactions
0 Visualizzazioni
(@Utente 0002)
Registrato: 1 secondo fa
Post: 0
  [#1637]

Il Gadoteridol , (10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium, Gadolinium 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, Gd-HP-DO3A
è un mezzo di contrasto paramagnetico, usato in risonanza magnetica come contrasto positivo in ponderazione T1.
E' indicato nello specifico nelle lesioni del parenchima cerebrale e midollare, non oltrepassa la barriera ematoencefalica normale.

Può essere somministrato anche a bolo, con dosaggio 0.1 mmol/kg(0.2 ml/kg) per la singola dose,

E' commercializzato dalla Bracco, con il nome di ProHance

[allegato non incluso]

Citazione
WARNING
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

  • Do not administer OptiMARK™ (gadoversetamide injection) to patients with:

    • chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
    • acute kidney injury (see CONTRAINDICATIONS).
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • Do not exceed the recommended OptiMARK™ (gadoversetamide injection) dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration (see WARNINGS).


   
Citazione
Condividi: